Crohn's disease
Transmural, skip-lesion inflammation anywhere from mouth to anus, most often terminal ileum. Progressive: most patients develop strictures or fistulae without effective control. Symptoms track inflammation poorly → treat to objective targets (calprotectin, endoscopy, imaging). Steroids induce, never maintain. 5-ASA has no role. Moderate–severe or high-risk disease → early advanced therapy, infliximab + thiopurine the strongest combination. Perianal fistula → drain sepsis first, then infliximab ± thiopurine; antibiotics as adjuncts (alone only for simple fistulae). Abscess >2 cm → drain before immunosuppression.
who needs early advanced therapy
Failure of conventional therapy is not a prerequisite for advanced therapy.
High-risk features (any → advanced therapy early):
- young age at diagnosis
- extensive bowel involvement; ileal/ileocolonic or upper GI disease
- perianal or severe rectal disease
- deep ulcers on colonoscopy
- stricturing or penetrating phenotype at diagnosis
- extraintestinal manifestations at diagnosis
PROFILE (2024): newly diagnosed active CD, infliximab + immunomodulator from the start vs accelerated step-up → sustained steroid- and surgery-free remission 79% vs 15% at 1 year, fewer surgeries. Open-label, but large effect.
Low-risk, mild disease (short ileal segment, older, no high-risk features) → budesonide induction, then monitor objectively. Untreated observation acceptable for mild asymptomatic disease with surveillance.
induction and maintenance
| severity / site | induction | maintenance |
|---|---|---|
| mild–moderate ileocaecal | budesonide 9 mg daily (ileal release) | none, or advanced therapy if relapses; budesonide doesn’t maintain |
| mild colonic | sulfasalazine (only 5-ASA with any colonic signal) | — |
| moderate–severe | prednisone 40–60 mg/day; assess at 2–4 weeks | advanced therapy; thiopurine or SC/IM methotrexate after steroid induction |
| severe, hospitalised | IV methylprednisolone 40–60 mg/day; assess within 1 week; infliximab inpatient if severe | — |
- Oral 5-ASA: against for induction and maintenance of CD.
- Systemic antibiotics don’t treat luminal inflammation.
- Thiopurines alone don’t induce (slow onset ~3 months) — useful for maintenance after steroids and to reduce anti-drug antibodies with anti-TNF.
- TPMT (± NUDT15) before azathioprine — deficiency → myelosuppression.
- Steroid dependence or resistance → advanced therapy, not repeated courses.
choosing an advanced therapy
All are recommended for moderate–severe CD. General choice (infection risk, loss of response, biosimilars), screening and toxicities → IBD advanced therapies. CD-specific points:
| situation | preferred |
|---|---|
| biologic-naive, high risk, perianal disease | infliximab + thiopurine (SONIC (2010): steroid-free remission at 26 wk 57% combination vs 44% infliximab vs 30% azathioprine) |
| prior anti-TNF failure | risankizumab over ustekinumab (conditional, low evidence); upadacitinib |
| active spondyloarthritis | anti-TNF |
perianal fistulising disease
- MRI pelvis (or EUS) ± examination under anaesthesia to map fistula and abscess.
- Drain abscesses and place setons first — advanced therapy on undrained sepsis → abscess.
- Infliximab (± thiopurine) is first-line; adalimumab an alternative. Vedolizumab, ustekinumab and upadacitinib have weaker data.
- Ciprofloxacin/metronidazole improve response when added to anti-TNF; alone they’re acceptable only for simple fistulae, and relapse on stopping.
Antibiotics are an adjunct, not the treatment — complex perianal fistula needs anti-TNF after surgical drainage.
complications
Intra-abdominal abscess → CT or MR → abscess >2 cm: antibiotics + percutaneous or surgical drainage; hold immunosuppression until drained. Most eventually need resection of the diseased segment.
Stricture — distinguish inflammatory from fibrotic by imaging and endoscopy:
- active inflammation (enhancement, ulceration, raised CRP) → advanced therapy
- fibrostenotic, short segment → endoscopic balloon dilation; long or multiple → resection or strictureplasty
Bowel obstruction, perforation, refractory bleeding, dysplasia/cancer → surgery.
Ileal resection → bile acid diarrhoea (bile acid sequestrant); >100 cm resected → fat malabsorption and steatorrhoea instead; B12 deficiency (chronic diarrhoea).
after surgery
Endoscopic recurrence in ~50% within 1–3 years; symptomatic recurrence ~50% at 5 years.
| risk | approach |
|---|---|
| low (non-smoker, no penetrating disease, first resection) | no treatment; colonoscopy at 6–12 months |
| intermediate (penetrating, first resection) | thiopurine ± metronidazole; colonoscopy at 6 months |
| high (prior resection, smoker) | anti-TNF ± immunomodulator (vedolizumab alternative) |
Rutgeerts ≥i2b at 6-month colonoscopy → escalate.
monitoring and long-term care
- Targets: symptom remission + normal CRP and calprotectin + endoscopic healing. Calprotectin above ~50–100 µg/g (assay-dependent) separates inflammatory from functional symptoms.
- Stool culture and C. difficile (clostridioides difficile infection) with every flare.
- Smoking cessation — smoking worsens CD (opposite of UC) and accelerates post-operative recurrence.
- NSAIDs can trigger flares — avoid routine use.
- CRC surveillance colonoscopy for Crohn’s colitis involving >30% of the colon, from 8 years after diagnosis; PSC → from diagnosis regardless of extent (ulcerative colitis); a first-degree relative with CRC adds risk (cancer screening — Canadian guidelines).
- Bone health (steroids, malabsorption), iron, B12, vitamin D; depression and anxiety screening.
- Vaccines and pre-therapy screening → IBD advanced therapies.
distinguishing CD from UC
| Crohn’s | UC | |
|---|---|---|
| distribution | skip lesions, mouth to anus; terminal ileum most often | continuous from rectum |
| depth | transmural → fistula, stricture, abscess | mucosal |
| rectum | often spared | always involved |
| perianal disease | common | no |
| histology | non-caseating granulomas (minority) | crypt abscesses, no granulomas |
| smoking | worsens | protective |
Prepared 2026-10-28. Not yet verified — check every number against the sources.